Dr Krishna Ella

Supplies will be prioritised for the public market through a direct procurement by the Government of Brazil, private market will…

The company is developing this a single dose intranasal vaccine for COVID-19 in partnership with Washington University School of…

They said that the important task in front of them is saving the lives and livelihoods of populations in India and the world

Dr Krishna Ella, Chairman and MD Bharat Biotech said that Covaxin trials '200 per cent honest'

Naidu stressed the importance of PPPs in coming out with indigenous world-class products

Ocugen will have US rights to the vaccine candidate and, in collaboration with Bharat Biotech, will be responsible for clinical…

COVAXIN has been evaluated in approximately 1000 subjects in Phase I and Phase II clinical trials, with promising safety and…

Dr Ella informs that the best of the technology will be put in the Odisha unit at a total investment of around Rs 300 crores

Bharat Biotech has announced its novel coronavirus vaccine COVAXIN approved for human trials, will use adjuvant Alhydroxiquim-II…

Bharat Biotech owns the rights to distribute the chimp-adenovirus, single-dose intranasal vaccine candidate in all markets except…